Nov 18 (Reuters) - The US FDA on Wednesday approved Sanofi's oral drug venglustat, the first treatment approved for a type of rare genetic condition affecting the brain and nervous system.
The drug, branded as Infilbray, is approved to treat type 3 Gaucher disease, the neurological variant of the disorder that causes certain fatty substances to accumulate in organs and tissues.
Under new CEO Belén Garijo, Sanofi is seeking to reduce its reliance on the blockbuster asthma drug Dupixent, which is set
to lose key patent exclusivity by the early 2030s.
Sanofi’s portfolio already includes therapies to treat Gaucher disease: Cerdelga for type 1 and Cerezyme for symptoms outside the brain and nervous system in patients with types 1 and 3.
Infilbray, however, can cross into the brain, allowing it to treat worsening problems with balance, coordination, speech, memory and thinking in type 3 disease.
It works by lowering the production of the fatty substances, unlike therapies such as Cerezyme, which supply the missing enzyme in Gaucher disease.
The approval for adults and children weighing at least 15 kilograms, or about 33 pounds, was based on a late-stage study of 43 patients aged 12 and older whose symptoms outside the brain had been stabilized with enzyme replacement therapy.
Patients receiving Infilbray once daily for 52 weeks improved on a combined measure of muscle control, coordination and thinking ability compared with those receiving enzyme replacement therapy every two weeks.
Infilbray is under regulatory review for type 3 Gaucher disease in the European Union and Japan, Sanofi said.
FDA ISSUES WARNINGS
The health agency said the most frequently reported side effects included digestive problems and changes in mood, and warned of serious psychiatric risks, including suicidal thoughts and behavior.
Animal studies have identified potential vision clouding in younger patients and adverse effects on fetal development, it said.
(Reporting by Kamal Choudhury and Kunal Das in Bengaluru and Bhanvi Satija in London; Editing by Sahal Muhammed and Rashmi Aich)













